| P/E (FY) | 20.3 | Sales (TTM) | $2.38B |
| Earnings (TTM) | $833.4M | ROE | 35.53% |
| Net Margin | 33.73% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | 70.59% | Sales Growth 3Y | 12.93% |
Exelixis is an oncology company focused on the discovery, development, and commercialization of medicines for difficult-to-treat cancers in the United States. It offers CABOMETYX tablets for advanced renal cell carcinoma and COMETRIQ capsules for medullary thyroid cancer, both derived from cabozantinib, along with COTELLIC for advanced melanoma and MINNEBRO for hypertension in Japan. The company is also developing zanzalintinib, an oral kinase inhibitor.
| Market Cap | $14.20B | Trading Days | 5293 |
| 52W High | 57.57 |
| 52W Low | 33.76 |
| % Off High | −1.84% |
| YTD | 28.93% | 1Y | 27.30% |
| 3Y | 184.69% | 5Y | 229.70% |
| 10Y | 531.40% | Since incept. (ann.) | 9.48% |
Reportable 100%
| Ann. Volatility (1Y) | 38.88% | Ann. Volatility (3Y) | 36.72% |
| Sharpe (1Y) | 0.83 | Sharpe (3Y) | 1.15 |
| Max Drawdown (1Y) | −22.19% | Max Drawdown (3Y) | −25.34% |
| Beta (3Y, vs SPY) | 0.32 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TECH | BIO-TECHNE Corp | $11.28B | 156.7 |
| NBIX | NEUROCRINE BIOSCIENCES INC | $18.38B | 39.1 |
| KRYS | Krystal Biotech, Inc. | $10.74B | 53.3 |
| HALO | HALOZYME THERAPEUTICS, INC. | $9.90B | 32.6 |
| QGEN | QIAGEN N.V. | $9.17B | — |
| MRNA | Moderna, Inc. | $22.14B | — |
| KYMR | Kymera Therapeutics, Inc. | $8.73B | — |
| RGEN | REPLIGEN CORP | $8.20B | 169.0 |
| APGE | Apogee Therapeutics, Inc. | $8.14B | — |
| IMVT | Immunovant, Inc. | $7.99B | — |
| PCVX | Vaxcyte, Inc. | $7.88B | — |
| IBRX | ImmunityBio, Inc. |
| $7.30B |
| — |
